v3.26.1
Balance Sheet Details
 6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Details Balance Sheet Details
Prepaid Expenses
Prepaid expenses consisted of the following:
June 30, 2026December 31, 2025
Prepaid research and development expenses$672 $106 
Prepaid insurance825 438 
Prepaid professional fees104 371 
Prepaid other139 154 
   Total prepaid expenses$1,740 $1,069 
Accrued Liabilities
Accrued liabilities consisted of the following:
June 30, 2026December 31, 2025
Accrued research and development costs$853 $1,522 
Accrued professional fees735 764 
Accrued other94 41 
   Total accrued liabilities$1,682 $2,327 

PanCAN Grant Agreement
In 2023, we were selected by the Pancreatic Cancer Action Network (“PanCAN”), a not-for-profit entity, as the recipient of its Therapeutic Accelerator Award to conduct a clinical trial with pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor in pancreatic cancer patients. Under the terms of the award agreement, we are entitled to receive up to $5,000 in funding for eligible research expenses, and we must comply with the conditions set out in the award agreement, including providing periodic performance progress reports.
Funding received for the three and six months ended June 30, 2026 was nil. Funding received for the three and six months ended June 30, 2025 was $1,125. During the three and six months ended June 30, 2026, we recognized $258 and $648, respectively, as a reduction of research and development expenses based on eligible costs incurred in accordance with the agreement. During the three and six months ended June 30, 2025, we recognized $774 and $1,530, respectively, as a reduction of research and development expenses based on eligible costs incurred in accordance with the agreement.
As of June 30, 2026 and December 31, 2025, eligible research and development expenditures incurred exceeded cumulative funding received to date, resulting in other receivables of $1,175 and $527, respectively.